How much does Blood Cancer UK Research make?

Blood Cancer UK Research reported revenue of £21.1m and a loss of £80k in the year to 31 Mar 2025, according to its accounts filed at Companies House.

How many employees does Blood Cancer UK Research have?

Blood Cancer UK Research reported an average of 131 employees in the year to 31 Mar 2025.

Is Blood Cancer UK Research profitable?

No — Blood Cancer UK Research reported a loss of £80k in the year to 31 Mar 2025.

Company No. 00738089 · Incorporated 17 Oct 1962

Blood Cancer UK Research

Registered name: BLOOD CANCER UK RESEARCH

Blood Cancer UK Research made £21.1m revenue and a £80k loss in the year to 31 Mar 2025.

Blood Cancer UK Research’s revenue grew 14% to £21.1m in the year to 31 Mar 2025, with a loss of £80k and 131 employees. The company is classified under “other research and experimental development on natural sciences and engineering” and is based in London; we hold 2 years of its filed accounts.

Full P&L filedSection M · Professional, scientific and technical activitiesSIC 72190Other research and experimental development on natural sciences and engineering SIC 86900Other human health activities

Status: Active
Location: London, London
Age: 64 yrs · since 1962
Type: PRI/LTD BY GUAR/NSC (Private, limited by guarantee, no share capital)

Non-profit. It is limited by guarantee (typically an association, club or management company), so it isn't run for profit. It is excluded from our opportunity lists.

Latest accounts · year to 31 Mar 2025

Key figures

Independent

Revenue

£21.1m

Growth ▲14.1%

Profit

−£80k

Growth ▼102.8%

Profit margin

−0.4%

Employees

131

Change ▲4%

Profit / employee

−£611

Revenue/employee £161k

Profitable streak

0yrs

Consecutive profitable years in our data

Badges are automated estimates derived from the filed figures — not statements of fact about the company.

2 filed years

Financial history

Multi-year financials, oldest to newest
Year to	31 Mar 2024	31 Mar 2025
Disclosure	Full P&L	Full P&L
Profit & loss
Revenue (turnover)	£18.5m	£21.1m
Operating profit	£1.7m	£839k
Profit before tax	£1.7m	£839k
Profit after tax	£2.8m	−£80k
Profit (best available)	£2.8m	−£80k
Employees (average)	126	131
Ratios
Profit margin	15.4%	−0.4%
Revenue per employee	£147k	£161k
Profit per employee	£22.6k	−£611
Growth (year on year)
Revenue growth	—	▲14.1%
Profit growth	—	▼102.8%
Headcount growth	—	▲4%
Balance sheet — indirect signals, not revenue
Net assets	—	—
Source	Accounts · bulk data Nov 2025	Accounts · bulk data Nov 2025

Derived from the latest filing

How the business works

Profit margin: −0.4%; Profit ÷ revenue.
Gross margin: —; Gross profit ÷ revenue. High for software and services.
Revenue per employee: £161k; Revenue ÷ average employees.
Profit per employee: −£611; Profit ÷ average employees.
Cash conversion: —; Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
Fixed assets ÷ revenue: —; Capital intensity. Low = capital-light, cheaper to start.
Deferred income ÷ revenue: —; Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
Debtors ÷ revenue: —; Money owed by customers. Low = customers pay quickly.

Indirect — not revenue

Balance-sheet signals

Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.

Net assets: —; Now —
Cash at bank: —; Now —
Headcount: ▲4%; Now 131
Deferred income: —; Now —
Fixed assets: —; Now —

Corporate ownership

Group structure

Subsidiaries (3)

Bloodwise Trading LimitedRev. £598k · Profit £464k
Bloodwise LtdFigures not disclosed
Leukaemia & Lymphoma Research LimitedFigures not disclosed

From the Persons with Significant Control register (corporate controllers only).

Same industry, similar size

Similar profitable businesses

Industry benchmarks →

Sources

Companies House profile Filing history & original accounts

Latest figures from accounts for the year to 31 Mar 2025 (profit −£80k), from the Companies House accounts bulk data published Nov 2025. Spotted an error? Request a correction.

Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.